Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Kazia Therapeutics Ltd ADR (KZIA)

Kazia Therapeutics Ltd ADR (KZIA)
0.9125 x 8 1.2500 x 1
Pre-market by (Cboe BZX)
0.9550 -0.0450 (-4.50%) 03/18/25 [NASDAQ]
0.9125 x 8 1.2500 x 1
Pre-market 0.9550 unch (unch) 15:11 ET
Quote Overview for Tue, Mar 18th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.9400
Day High
1.0100
Open 1.0100
Previous Close 1.0000 1.0000
Volume 31,500 31,500
Avg Vol 368,020 368,020
Stochastic %K 33.25% 33.25%
Weighted Alpha -87.59 -87.59
5-Day Change +0.0566 (+6.30%) +0.0566 (+6.30%)
52-Week Range 0.7560 - 15.8000 0.7560 - 15.8000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,809
  • Shares Outstanding, K 5,036
  • Annual Sales, $ 1,630 K
  • Annual Income, $ -17,560 K
  • EBIT $ 0 M
  • EBITDA $ -17 M
  • 60-Month Beta 2.28
  • Price/Sales 3.33
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/21/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 1,149.82% ( +869.96%)
  • Historical Volatility 147.52%
  • IV Percentile 97%
  • IV Rank 87.04%
  • IV High 1,306.19% on 09/16/24
  • IV Low 99.27% on 08/07/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 15
  • Volume Avg (30-Day) 22
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 1,393
  • Open Int (30-Day) 1,415

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7560 +26.32%
on 03/04/25
Period Open: 0.9000
1.4400 -33.68%
on 03/07/25
+0.0550 (+6.11%)
since 02/18/25
3-Month
0.7560 +26.32%
on 03/04/25
Period Open: 2.8500
3.2600 -70.71%
on 12/19/24
-1.8950 (-66.49%)
since 12/18/24
52-Week
0.7560 +26.32%
on 03/04/25
Period Open: 2.3250
15.8000 -93.96%
on 07/11/24
-1.3700 (-58.92%)
since 03/18/24

Most Recent Stories

More News
Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women

/CNW/ -- With every October, breast cancer awareness surges thanks to very effective campaigns and new developments in breast cancer treatment. However, this...

ONCY : 0.6067 (-3.01%)
HOLX : 61.98 (+0.26%)
KZIA : 0.9550 (-4.50%)
ATOS : 0.7249 (-0.73%)
NVS : 112.22 (unch)
ONC.TO : 0.87 (-2.25%)
KZA.AX : 0.080 (+9.59%)
Kazia announces voluntary delisting from ASX

/PRNewswire/ -- Kazia Therapeutics Limited (ASX:KZA, NASDAQ:KZIA) (Kazia or the Company), an oncology-focused drug development company, announces its intention...

KZIA : 0.9550 (-4.50%)
KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update regarding...

KZIA : 0.9550 (-4.50%)
KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that data from an...

KZIA : 0.9550 (-4.50%)
KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that its lead...

KZIA : 0.9550 (-4.50%)
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it is supporting...

KZIA : 0.9550 (-4.50%)
DAWN : 8.16 (-5.88%)
NVS : 112.22 (unch)
KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, has been invited to the White House to...

KZIA : 0.9550 (-4.50%)
KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to have received notification...

KZIA : 0.9550 (-4.50%)
KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of...

KZIA : 0.9550 (-4.50%)
KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS

/PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce a placement...

KZIA : 0.9550 (-4.50%)

Business Summary

Kazia Therapeutics Limited is an oncology-focused biotechnology company. It develops anti-cancer drugs as well as provides pharmaceutical research and development technology solutions. The company's lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being...

See More

Key Turning Points

3rd Resistance Point 1.0667
2nd Resistance Point 1.0383
1st Resistance Point 0.9967
Last Price 0.9550
1st Support Level 0.9267
2nd Support Level 0.8983
3rd Support Level 0.8567

See More

52-Week High 15.8000
Fibonacci 61.8% 10.0532
Fibonacci 50% 8.2780
Fibonacci 38.2% 6.5028
Last Price 0.9550
52-Week Low 0.7560

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals